Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

Exclusion Criteria

• •1. Hypertriglyceridemia \> 500 mg/dL at screening.
• •2. BMI \> 40 kg/m2.
• •3. Receiving thiazolidinediones, insulin, or exenatide within the 3 months prior to screening.
• •4. History or clinical manifestations of Addison's disease, Cushing's Syndrome, or other disorders involving glucocorticoids or mineralocorticoids.
• •5. Current treatment or treatment within 30 days or five half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational protocol.